572-Trii (HIV) - Forecast and Market Analysis to 2022
NEW YORK, April 16, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
572-Trii (HIV) - Forecast and Market Analysis to 2022
572-Trii (HIV) - Forecast and Market Analysis to 2022
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, "572-Trii (HIV) - Forecast and Market Analysis to 2022". Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.
ViiV is developing a new HIV regimen known as 572-Trii. The single-pill, complete-regimen contains the investigational integrase inhibitor, dolutegravir (S/GSK1349572) and ViiV Healthcare's Epzicom, which contains the NRTIs abacavir (ABC) and lamivudine (3TC). 572-Trii's mechanism of action involves the following -
- Dolutegravir, as an integrase inhibitor, targets HIV integrase, an enzyme that is required for the integration of viral DNA into the host cell genome. Inhibiting integrase prevents HIV from replicating and propagating (Isentress Highlights of Prescribing Information, 2012).
- ABC, a carbocyclic synthetic nucleoside analog, is converted into its active form, carbovir triphosphate, by normal metabolic processes. Carbovir triphosphate inhibits the activity of HIV reverse transcriptase (RT) both by competing with a natural substrate deoxyguanosine 5'-triphosphate and by being incorporated into nascent viral DNA, resulting in the termination of replication (Epzicom Highlights of Prescribing Information, 2012).
- 3TC, a synthetic nucleoside analog, is converted into its active form, lamivudine triphosphate, by normal metabolic processes. Lamivudine triphosphate inhibits the activity of HIV RT by terminating viral replication after the drug is incorporated into the viral DNA (Epzicom Highlights of Prescribing Information, 2012).
Scope
- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on 572-Trii including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for 572-Trii for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of 572-Trii performance
- Obtain sales forecast for 572-Trii from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)
Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 13
3.1.3 Prognosis 13
3.1.4 Quality of Life 14
3.2 Symptoms 14
3.2.1 Primary or Acute Infection 14
3.2.2 Chronic Infection 14
3.2.3 Advanced Infection/AIDS 15
4 Disease Management 16
4.1 Treatment Overview 16
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Opportunity and Unmet Need 23
6.1 Overview 23
6.1.1 Simplified regimens and dosing frequency 24
6.1.2 Side effects and toxicities 24
6.1.3 Drug resistance 25
6.1.4 Prophylaxis 25
6.1.5 Lack of functional cure 26
6.1.6 Patient awareness 26
6.1.7 Treatment availability 27
6.1.8 Treatment affordability 28
6.2 Unmet Needs Gap Analysis 29
6.3 Opportunities 31
6.3.1 Development of treatments to counter drug resistance 31
6.3.2 Collaborations to develop newer STRs 31
6.3.3 Development of new injectable formulations 31
6.3.4 Development of new prophylactics 32
6.3.5 Development of drugs that use a novel mechanism of action 32
6.3.6 Public-Private Partnerships 32
7 Pipeline Assessment 33
7.1 Overview 33
7.2 Promising Drugs in Clinical Development 35
8 572-Trii 37
8.1 Overview 37
8.2 Efficacy 39
8.3 Safety 39
8.4 Dosing and Formulation 39
8.5 Potential Clinical Positioning 40
8.6 Potential Commercial Positioning 40
8.7 Pricing and Reimbursement 40
8.8 SWOT Analysis 41
8.9 Forecast 43
9 Appendix 44
9.1 Bibliography 44
9.2 Abbreviations 48
9.3 Methodology 50
9.4 Forecasting Methodology 50
9.4.1 HIV Prevalence 50
9.4.2 Percent Drug-Treated Patients 50
9.4.3 General Pricing Assumptions 51
9.4.4 Generic Erosion 52
9.4.5 Pricing of Pipeline agents 52
9.5 Physicians and Specialists Included in this Study 53
9.5.1 Survery of Prescribing Physicians 54
9.6 About the Authors 55
9.6.1 Authors 55
9.6.2 Global Head of Healthcare 56
9.7 About GlobalData 57
9.8 Contact Us 57
9.9 Disclaimer 57
List of Tables
Table 1: Symptoms HIV 15
Table 2: Treatment Guidelines for HIV 17
Table 3: Most Prescribed Drugs for HIV by Class in the Global Markets, 2012 18
Table 4: Leading Treatments for HIV, 2012 22
Table 5: Overall Unmet Needs – Current Level of Attainment 23
Table 6: Clinical Unmet Needs – Gap Analysis, 2012 30
Table 7: HIV – Promising Drugs in Clinical Development, 2012 35
Table 8: Comparison of Therapeutic Classes in Development for HIV, 2012 36
Table 9: Product Profile – 572-Trii 38
Table 10: 572-Trii SWOT Analysis, 2012 42
Table 11: Global Sales Forecasts ($m) for Pipeline 572-Trii, 2012–2022 43
Table 12: Physicians Surveyed, By Country 54
List of Figures
Figure 1: HIV Lifecycle 11
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2012–2022 35
To order this report:
Pathology Industry: 572-Trii (HIV) - Forecast and Market Analysis to 2022
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article